Statins and clinical outcomes in hospitalized COVID-19 patients with and without Diabetes Mellitus: a retrospective cohort study with propensity score matching
Open Access
- 10 July 2021
- journal article
- research article
- Published by Springer Science and Business Media LLC in Cardiovascular Diabetology
- Vol. 20 (1), 1-15
- https://doi.org/10.1186/s12933-021-01336-0
Abstract
The pleiotropic effects of statins may reduce the severity of COVID-19 disease. This study aims to determine the association between inpatient statin use and severe disease outcomes among hospitalized COVID-19 patients, especially those with Diabetes Mellitus (DM). A retrospective cohort study on hospitalized patients with confirmed COVID-19 diagnosis. The primary outcome was mortality during hospitalization. Patients were classified into statin and non-statin groups based on the administration of statins during hospitalization. Analysis included multivariable regression analysis adjusting for confounders and propensity score matching to achieve a 1:1 balanced cohort. Subgroup analyses based on presence of DM were conducted. In the cohort of 922 patients, 413 had a history of DM. About 27.1% patients (n = 250) in the total cohort (TC) and 32.9% patients (n = 136) in DM cohort received inpatient statins. Atorvastatin (n = 205, 82%) was the most commonly prescribed statin medication in TC. On multivariable analysis in TC, inpatient statin group had reduced mortality compared to the non-statin group (OR, 0.61; 95% CI, 0.42–0.90; p = 0.01). DM modified this association between inpatient statins and mortality. Patients with DM who received inpatient statins had reduced mortality (OR, 0.35; 95% CI, 0.21–0.61; p < 0.001). However, no such association was noted among patients without DM (OR, 1.21; 95% CI, 0.67–2.17; p = 0.52). These results were further validated using propensity score matching. Inpatient statin use was associated with significant reduction in mortality among COVID-19 patients especially those with DM. These findings support the pursuit of randomized clinical trials and inpatient statin use appears safe among COVID-19 patients.Keywords
This publication has 44 references indexed in Scilit:
- Statins May Decrease the Fatality Rate of Middle East Respiratory Syndrome InfectionmBio, 2015
- Toll-Like Receptor 3 Signaling via TRIF Contributes to a Protective Innate Immune Response to Severe Acute Respiratory Syndrome Coronavirus InfectionmBio, 2015
- Immunological mechanisms contributing to the double burden of diabetes and intracellular bacterial infectionsImmunology, 2015
- Fluvastatin Causes NLRP3 Inflammasome-Mediated Adipose Insulin ResistanceDiabetes, 2014
- 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in AdultsJournal of the American College of Cardiology, 2014
- Inhibition of protein geranylgeranylation and farnesylation protects against graft-versus-host disease via effects on CD4 effector T cellsHaematologica, 2012
- Statins and Pulmonary FibrosisAmerican Journal of Respiratory and Critical Care Medicine, 2012
- Statins and the vascular endothelial inflammatory responseTrends in Immunology, 2007
- Effect of pravastatin on plasma markers of inflammation and peripheral endothelial function in male heart transplant recipientsThe American Journal of Cardiology, 2001
- Vascular function in the forearm of hypercholesterolaemic patients off and on lipid-lowering medicationThe Lancet, 1995